Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers.

Suryadi J, Bierbach U.

Chemistry. 2012 Oct 8;18(41):12926-34. doi: 10.1002/chem.201202050.

PMID:
22987397
2.

Adenine-N3 in the DNA minor groove - an emerging target for platinum containing anticancer pharmacophores.

Guddneppanavar R, Bierbach U.

Anticancer Agents Med Chem. 2007 Jan;7(1):125-38. Review.

PMID:
17266509
3.
4.

Current status of the development of trans-platinum antitumor drugs.

Pérez JM, Fuertes MA, Alonso C, Navarro-Ranninger C.

Crit Rev Oncol Hematol. 2000 Aug;35(2):109-20. Review.

PMID:
10936468
5.

[Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].

Chatelut E.

Bull Cancer. 2011 Nov;98(11):1253-61. doi: 10.1684/bdc.2011.1464. Review. French.

6.

Novel concepts in the development of platinum antitumor drugs.

Fuertes MA, Castilla J, Alonso C, Pérez JM.

Curr Med Chem Anticancer Agents. 2002 Jul;2(4):539-51. Review.

PMID:
12678734
7.

DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.

Brabec V.

Prog Nucleic Acid Res Mol Biol. 2002;71:1-68. Review.

PMID:
12102553
8.

New platinum antitumor complexes.

Kelland LR.

Crit Rev Oncol Hematol. 1993 Dec;15(3):191-219. Review.

PMID:
8142057
9.

Oxaliplatin: mechanism of action and antineoplastic activity.

Raymond E, Faivre S, Woynarowski JM, Chaney SG.

Semin Oncol. 1998 Apr;25(2 Suppl 5):4-12. Review.

PMID:
9609103
10.

NMR spectroscopy of anticancer platinum drugs.

Vinje J, Sletten E.

Anticancer Agents Med Chem. 2007 Jan;7(1):35-54. Review.

PMID:
17266504
11.

Multi-nuclear platinum drugs: a new paradigm in chemotherapy.

Wheate NJ, Collins JG.

Curr Med Chem Anticancer Agents. 2005 May;5(3):267-79. Review.

PMID:
15992354
12.

Photoactivatable platinum complexes.

Bednarski PJ, Mackay FS, Sadler PJ.

Anticancer Agents Med Chem. 2007 Jan;7(1):75-93. Review.

PMID:
17266506
13.

Molecular aspects of resistance to antitumor platinum drugs.

Brabec V, Kasparkova J.

Drug Resist Updat. 2002 Jul-Aug;5(3-4):147-61. Review.

PMID:
12237082
14.

[Current status of and future perspectives for platinum antitumor drugs].

Chikuma M, Sato T, Komeda S.

Yakugaku Zasshi. 2008 Mar;128(3):307-16. Review. Japanese.

15.

Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.

Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR.

J Inorg Biochem. 1999 Oct;77(1-2):111-5. Review.

PMID:
10626362
16.

Trans-platinum complexes in cancer therapy.

Coluccia M, Natile G.

Anticancer Agents Med Chem. 2007 Jan;7(1):111-23. Review.

PMID:
17266508
17.

The potential of acridine carboxamide Pt complexes as anti-cancer agents : a review.

Murray V, Chen JK, Galea AM.

Anticancer Agents Med Chem. 2014 Jun;14(5):695-705. Review.

PMID:
24102313
18.

Status of bi- and multi-nuclear platinum anticancer drug development.

Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, Zhang Y.

Anticancer Agents Med Chem. 2010 May;10(4):272-82. Review.

PMID:
20184553
19.

New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

Reedijk J.

Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3611-6. Review.

20.

Unusual DNA binding modes for metal anticancer complexes.

Pizarro AM, Sadler PJ.

Biochimie. 2009 Oct;91(10):1198-211. doi: 10.1016/j.biochi.2009.03.017. Review.

Items per page

Supplemental Content

Support Center